Novel Lipid Lowering Therapy Against Coronary atherosclerosis: Role of PCSK9 Inhibitors - Masayuki Yoshida

↳ This is a section part of Moment: ISCP 2017 - Coronary Artery Disease - Joint Session ISCP and European Association of Professors Emeriti

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$21.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Novel Lipid Lowering Therapy Against Coronary atherosclerosis: Role of PCSK9 Inhibitors - Presented by Masayuki Yoshida at ISCP 2017.

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$21.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Cardiologists, interventional Cardiologists
  • Interventional Fellows
  • Interventional Radiologists
  • Vascular Surgeons
  • Emergency Physicians

Learning Objectives

Other Components in this Moment

Overview
Chest Pain in Aortic Stenosis: Novel Diagnostic and therapeutic Data - Dennis Cokkinos
Antiplatelets After PCI in 2017, Which Agents and for how Long? - Pablo Avanzas
Role of Life-Style in the Prevention of the Risk Factors of Coronary Artery Disease - Mário Maranhão
Management of Microvascular Angina - Juan Carlos Kaski
Ranolazine - Pharmacological Characteristics and therapeutic Effects - Juan Tamargo
Novel Lipid Lowering Therapy Against Coronary atherosclerosis: Role of PCSK9 Inhibitors - Masayuki Yoshida
Improving Persistence and Clinical Results of Drug Therapy: The Role of a Polypill - José María Castellano
Discussion of ISCP 2017 - Coronary Artery Disease - Joint Session ISCP and European Association of Professors Emeriti
Loading Simple Education